This study, called MAINTAIN, is looking at a procedure called Gastric Fundal Mucosal Ablation (GFMA) to help people maintain weight loss after stopping medications like semaglutide or tirzepatide. These medications help with weight loss, but people often regain weight when they stop taking them. GFMA is an endoscopic procedure, meaning it uses a thin, flexible tube with a camera. You might be able to join if you are between 21 and 65 years old, have a Body Mass Index (BMI) between 30 and 45, and have lost at least 10% of your body weight using semaglutide or tirzepatide. The study aims to see how much weight participants maintain 12 months after the procedure. The study plans to enroll 20 participants, but its current recruitment status is unclear.

Study design

This is an interventional study with a planned enrollment of 20 participants. The study is investigating the effect of Gastric Fundal Mucosal Ablation (GFMA).

What's involved

You would undergo an endoscopic Gastric Fundal Mucosal Ablation (GFMA) procedure after stopping your GLP-1 medication.

Compensation

Not stated in the trial record.

Follow-up

Your total body weight loss will be measured at 12 months after the procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.